This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lin, S. Articles by Chien, D. Search for Related Content PubMed PubMed Citation Articles by Lin, S. Articles by Chien, D.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, August 2005, p. 3917-3924, Vol. 43, No. 8
0095-1137/05/$08.00+0     doi:10.1128/JCM.43.8.3917-3924.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Design of Novel Conformational and Genotype-Specific Antigens for Improving Sensitivity of Immunoassays for Hepatitis C Virus-Specific Antibodies

Chiron Corporation, 4560 Horton St., Emeryville, California 94608

Received 21 December 2004/ Returned for modification 31 January 2005/ Accepted 26 April 2005

The current commercially licensed enzyme-linked immunosorbent assays (ELISAs) for hepatitis C virus (HCV) mainly use recombinant proteins containing linear epitopes. There is evidence, however, that conformational epitopes of HCV are more immunoreactive. Thus, we have designed an HCV antibody assay that employs a conformational protein, NS3NS4a PI (with functional protease and helicase activities), and a linear fusion protein, multiple-epitope fusion antigen 7.1 (MEFA 7.1) or MEFA 7.2. We have shown that NS3NS4a PI detects early-seroconversion conformation-sensitive antibodies better than c33c antigen. The correct conformation of NS3NS4a PI also cross-reacts with different genotype samples better than the c33c antigen. MEFA 7.1 and MEFA 7.2 incorporate all the major immunodominant and genotype-specific epitopes of HCV core, E1, E2 hypervariable region 1 (HVR1), E2 HVR1-plus-HVR2 consensus, NS3, NS4, and NS5. Since MEFA 7.1 is degraded by the active NS3NS4a PI protease, we designed a second MEFA 7.2 construct in which the six protease cleavage sites found in MEFA 7.1 were eliminated by amino acid mutation. We demonstrate here that MEFA 7.2 remains intact in the presence of NS3NS4a PI and preserves the epitopes present in MEFA 7.1. Compared to currently licensed assays, an ELISA incorporating a combination of the two antigens NS3NS4a PI and MEFA 7.1 or 7.2 demonstrates better serotype sensitivity and detects seroconversion earlier in many commercially available panels. We believe that an assay using NS3NS4a PI and MEFA 7.1 or 7.2 may have the potential to replace current HCV immunoassays for better sensitivity.

This article has been cited by other articles:

• Lara, J., Wohlhueter, R. M., Dimitrova, Z., Khudyakov, Y. E. (2008). Artificial neural network for prediction of antigenic activity for a major conformational epitope in the hepatitis C virus NS3 protein. Bioinformatics 24: 1858-1864 [Abstract] [Full Text]  
• Vajdy, M., Selby, M., Medina-Selby, A., Coit, D., Hall, J., Tandeske, L., Chien, D., Hu, C., Rosa, D., Singh, M., Kazzaz, J., Nguyen, S., Coates, S., Ng, P., Abrignani, S., Lin, Y.-L., Houghton, M., O'Hagan, D. T. (2006). Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses.. J. Gen. Virol. 87: 2253-2262 [Abstract] [Full Text]  
• Toellner, L., Fischlechner, M., Ferko, B., Grabherr, R. M., Donath, E. (2006). Virus-Coated Layer-by-Layer Colloids as a Multiplex Suspension Array for the Detection and Quantification of Virus-Specific Antibodies. Clin. Chem. 52: 1575-1583 [Abstract] [Full Text]